Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DWC 202314

Next Previous
Drug Profile

DWC 202314

Alternative Names: DWC-202314

Latest Information Update: 03 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daewoong Pharmaceutical
  • Class Antihypertensives
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Essential hypertension
  • Phase I Unspecified

Most Recent Events

  • 24 Feb 2025 Phase-III clinical trials in Essential hypertension (Combination therapy) in South Korea (PO) (NCT06671392)
  • 05 Nov 2024 Daewoong Pharmaceutical plans a phase III trial for Essential hypertension (Combination-therapy), in December 2024 (PO, Tablet) (NCT06671392)
  • 05 Nov 2024 Preclinical trials in Essential hypertension in South Korea (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top